Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/13957
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2016-11-15T14:12:28Z | - |
dc.date.available | 2016-11-15T14:12:28Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Pharmaceutical Research-based Industry Malta Association. (2014). Improving patient access to innovative medicines : the framework in which differentiated pricing may offer a solution. The Synapse, 13(3), 10-11 | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar//handle/123456789/13957 | - |
dc.description | Reproduced from a Position Paper published by the European Federation of Pharmaceutical Industries and Associations, February 2014 | en_GB |
dc.description.abstract | The research-based pharmaceutical industry considers that price differentiation between EU Member States could greatly improve affordable patient access to innovative medicines in those markets where there is a significant access problem. Adapting prices of pharmaceuticals to reflect the ability to pay in different geographical or even socio-economic segments can offer a win-win situation in terms of generating dynamic efficiencies that contribute to both the sustainability of healthcare systems and the pace of innovation. Yet today’s pricing and reimbursement practices have the effect of discouraging price differentiation. Member State action and support from the European Union are required to create a framework to enable and encourage voluntary recourse to differentiated pricing. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | Medical Portals Ltd. | en_GB |
dc.rights | info:eu-repo/semantics/openAccess | en_GB |
dc.subject | Drugs -- Prices | en_GB |
dc.subject | Pricing -- European Union countries | en_GB |
dc.subject | Prescription pricing -- European Union countries | en_GB |
dc.subject | Pharmaceutical policy -- European Union countries | en_GB |
dc.subject | Pharmaceutical industry -- Prices -- European Union countries | en_GB |
dc.title | Improving patient access to innovative medicines : the framework in which differentiated pricing may offer a solution | en_GB |
dc.title.alternative | Differentiated pricing may offer a solution | en_GB |
dc.type | article | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder. | en_GB |
dc.contributor.corpauthor | Pharmaceutical Research and Development Industry Malta Association (PRIMA) | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
Appears in Collections: | The Synapse, Volume 13, Issue 3 The Synapse, Volume 13, Issue 3 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Improving patient acces to innovative medicine.pdf | 223.12 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.